Skip to main content
NCBI home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1967 Mar 4;96(9):536–539.

A Comparison of the Effects of Tolazamide and Tolbutamide Upon Blood Glucose and Serum Insulin and Lipid Levels in Diabetic Subjects

J A Moorhouse
PMCID: PMC1936014  PMID: 6019354

Abstract

The effects of tolazamide (300 mg. daily), a new oral hypoglycemic sulfonylurea, and tolbutamide on the blood glucose, serum insulin, cholesterol and triglyceride levels were compared in 14 subjects with maturity-onset diabetes of varying severity. The mean effects of the two drugs in the pharmacologically equivalent doses were the same. In particular, the mean reduction of the blood glucose level was 19% and of the serum triglyceride level was 17% with both agents. However, an individual subject might respond to one agent and not to the other; neither the blood glucose nor the serum lipid response could be predicted from the pretreatment blood glucose level or the per cent of ideal body weight.

Full text

PDF
536

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ABELOVE W. A., ECHENIQUE R., HILLS A. G. Clinical evaluation of a new hypoglycemic sulfonylurea, tolazamide. A preliminary report on its chlorinated analogue, azepinamide. Diabetes. 1962 May-Jun;11:216–221. [PubMed] [Google Scholar]
  2. BECKETT A. G., DONOVAN R. J. TOLAZAMIDE (TOLANASE) -- A NEW SULPHONYLUREA. Br J Clin Pract. 1965 May;19:275–279. [PubMed] [Google Scholar]
  3. BRESSLER R., KATZ R. EVALUATION OF TOLAZAMIDE IN THE TREATMENT OF DIABETES MELLITUS. Curr Ther Res Clin Exp. 1965 Apr;7:219–225. [PubMed] [Google Scholar]
  4. DULIN W. E., OSTER H. L., McMAHON F. G. A new high potency antidiabetic sulfonylurea [N-(1-hexahydro-1-azepinyl)-N'-p-tolyl-sulfonylurea]. Proc Soc Exp Biol Med. 1961 Jun;107:245–248. doi: 10.3181/00379727-107-26591. [DOI] [PubMed] [Google Scholar]
  5. GRINNELL E. H., SKILLMAN T. G., BARSE R., MOLLER C. L., Jr CLINICAL EFFECTS OF A NEW, POTENT, NON-TOXIC SULFONYLUREA (TOLAZAMIDE). Curr Ther Res Clin Exp. 1964 Jul;6:433–441. [PubMed] [Google Scholar]
  6. LUCCHI R., ROBBA L. [1st clinical experience with a new oral hypoglycemic agent: tolazamide, 1-(hexahydro-1-azepinyl)-3-p-tolysulfonylurea]. Gazz Int Med Chir. 1962 Dec 15;67:2599–2609. [PubMed] [Google Scholar]
  7. RENNIE C. S., ANDERSON D. O. CLINICAL STUDIES OF TOLAZAMIDE AND TOLBUTAMIDE: COMPARATIVE EFFECTIVENESS OF CONTROL OF DIABETES MELLITUS. Can Med Assoc J. 1963 Sep 28;89:669–671. [PMC free article] [PubMed] [Google Scholar]
  8. STERN S. B., Jr CLINICAL STUDY OF TOLAZAMIDE: A NEW ANTIDIABETIC SULFONYLUREA. J La State Med Soc. 1965 Jun;117:198–202. [PubMed] [Google Scholar]
  9. TOOLAN T. J., WAGNER R. L., Jr The physical properties of chlorpropamide and its determination in human serum. Ann N Y Acad Sci. 1959 Mar 30;74(3):449–458. doi: 10.1111/j.1749-6632.1959.tb39568.x. [DOI] [PubMed] [Google Scholar]
  10. VAN HANDEL E., ZILVERSMIT D. B. Micromethod for the direct determination of serum triglycerides. J Lab Clin Med. 1957 Jul;50(1):152–157. [PubMed] [Google Scholar]
  11. WRIGHT L. A., TONKS D. B., ALLEN R. H. Determination of cholesterol with special reference to the use of p-toluene-sulfonic acid. Clin Chem. 1960 Jun;6:243–253. [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES